Nyrada Inc (NYR) - Total Liabilities

Latest as of December 2025: AU$548.97K AUD ≈ $388.43K USD

Based on the latest financial reports, Nyrada Inc (NYR) has total liabilities worth AU$548.97K AUD (≈ $388.43K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Nyrada Inc (NYR) cash conversion ratio to assess how effectively this company generates cash.

Nyrada Inc - Total Liabilities Trend (2018–2025)

This chart illustrates how Nyrada Inc's total liabilities have evolved over time, based on quarterly financial data. Check Nyrada Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Nyrada Inc Competitors by Total Liabilities

The table below lists competitors of Nyrada Inc ranked by their total liabilities.

Company Country Total Liabilities
Highlight Event Entertainment
SW:HLEE
Switzerland CHF609.16 Million
Dual Co Ltd
KO:016740
Korea ₩269.69 Billion
Jeil Pharm
KO:002620
Korea ₩400.33 Billion
ULMA Construccion Polska SA
WAR:ULM
Poland zł75.00 Million
Astro Malaysia Holdings Bhd
KLSE:6399
Malaysia RM3.84 Billion
ÖKOWORLD AG
XETRA:VVV3
Germany €24.57 Million
EPE Capital Partners Ltd
JSE:EPE
South Africa ZAC201.00 Million

Liability Composition Analysis (2018–2025)

This chart breaks down Nyrada Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Nyrada Inc.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 19.00 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.06 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.05 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Nyrada Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Nyrada Inc (2018–2025)

The table below shows the annual total liabilities of Nyrada Inc from 2018 to 2025.

Year Total Liabilities Change
2025-06-30 AU$1.72 Million
≈ $1.22 Million
+101.40%
2024-06-30 AU$855.63K
≈ $605.41K
-5.59%
2023-06-30 AU$906.28K
≈ $641.25K
+75.81%
2022-06-30 AU$515.48K
≈ $364.73K
-22.53%
2021-06-30 AU$665.38K
≈ $470.80K
-10.16%
2020-06-30 AU$740.67K
≈ $524.07K
-87.85%
2019-06-30 AU$6.10 Million
≈ $4.31 Million
+34.52%
2018-06-30 AU$4.53 Million
≈ $3.21 Million
--

About Nyrada Inc

AU:NYR Australia Biotechnology
Market Cap
$91.86 Million
AU$129.82 Million AUD
Market Cap Rank
#19515 Global
#645 in Australia
Share Price
AU$0.53
Change (1 day)
-7.02%
52-Week Range
AU$0.10 - AU$1.38
All Time High
AU$1.38
About

Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporat… Read more